The Substances on the Table These are the drugs being reviewed and the medical uses FDA will be evaluating: July 23, 2026: BPC-157 (free base and acetate) ulcerative colitis KPV (free base and acetate) wound healing and inflammatory conditions TB-500 (free base and acetate) wound healing MOTs-C (free base and acetate) obesity and osteoporosis July 24, 2026: Emideltide / DSIP (delta sleep-inducing peptide, free base and acetate) opioid withdrawal, chronic insomnia, and narcolepsy Semax (free base and acetate) cerebral ischemia, migraine, and trigeminal neuralgia Epitalon (free base and acetate) insomnia If any or all of these substances are added to the 503A Bulks List following this process, it would formalize the legal pathway for licensed pharmacists and physicians to compound them for patients
Many forms of bacterial contamination are not visible to the naked eye
Due to the high yield, give it a few extra minutes for the lyophilised solid to dissolve into a clear, slightly blue-tinted liquid
Implications for dietary supplements The outcome is being closely watched by the supplement industry as a growing number of companies explore bioactive peptides for applications ranging from healthy aging and metabolic health to sports nutrition, even as the regulatory framework for peptide ingredients remains unclear
Differential protein expression patterns and pathway enrichment Proteins were stratified into six distinct expression categories based on their temporal patterns across four timepoints: Group 1 (consistent increase), Group 2 (consistent decrease), Group 3 (increase then decrease), Group 4 (decrease then increase), Group 5 (up-down-up), and Group 6 (down-up-down) (Fig